Literature DB >> 16297603

Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (Part II).

George I Papakostas1, Dan V Iosifescu, Perry F Renshaw, In Kyoon Lyoo, Ho Kyu Lee, Jonathan E Alpert, Andrew A Nierenberg, Maurizio Fava.   

Abstract

The objective of this study was to investigate the relative impact of brain white matter hyperintensities (WMHs), cardiovascular risk factors and elements of the one-carbon cycle metabolism (including serum folate, vitamin B12 and homocysteine levels) on the outcome of antidepressant treatment in non-elderly subjects with major depressive disorder (MDD). Fifty MDD subjects were administered brain magnetic resonance imaging (MRI) scans at 1.5 T to detect T2 WMHs. The severity of brain WMHs was classified with the Fazekas scale (range=0-3). We assessed cardiovascular risk factors in all MDD subjects (age, gender, smoking, diabetes, family history, hypertension, cholesterol). MDD patients also had serum folate, vitamin B12 and homocysteine levels measured. All MDD subjects received treatment with fluoxetine 20 mg/day for 8 weeks. In a logistic regression, the severity of subcortical WMHs and the presence of hypofolatemia were independent predictors of lack of clinical response to antidepressant treatment. Separately, hypofolatemia also predicted lack of remission to antidepressant treatment. These associations were independent of the presence of smoking, diabetes, family history, hypercholesterolemia, hyperhomocysteinemia and low B12 levels. Although preliminary, the results of the present work suggest that subcortical brain WMHs and hypofolatemia may have an independent negative impact on the likelihood of responding to antidepressant treatment in non-geriatric subjects with MDD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16297603     DOI: 10.1016/j.pscychresns.2005.09.001

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  7 in total

Review 1.  Functional biomarkers of depression: diagnosis, treatment, and pathophysiology.

Authors:  Heath D Schmidt; Richard C Shelton; Ronald S Duman
Journal:  Neuropsychopharmacology       Date:  2011-08-03       Impact factor: 7.853

2.  L-methylfolate Plus SSRI or SNRI from Treatment Initiation Compared to SSRI or SNRI Monotherapy in a Major Depressive Episode.

Authors:  Lawrence D Ginsberg; Alondra Y Oubre; Yahya A Daoud
Journal:  Innov Clin Neurosci       Date:  2011-01

3.  Plasma homocysteine concentrations and depression: A twin study.

Authors:  J Douglas Bremner; Jack Goldberg; Viola Vaccarino
Journal:  J Affect Disord Rep       Date:  2021-01-16

Review 4.  Diet, Stress and Mental Health.

Authors:  J Douglas Bremner; Kasra Moazzami; Matthew T Wittbrodt; Jonathon A Nye; Bruno B Lima; Charles F Gillespie; Mark H Rapaport; Bradley D Pearce; Amit J Shah; Viola Vaccarino
Journal:  Nutrients       Date:  2020-08-13       Impact factor: 5.717

Review 5.  Predictors, moderators, and mediators (correlates) of treatment outcome in major depressive disorder.

Authors:  George I Papakostas; Maurizio Fava
Journal:  Dialogues Clin Neurosci       Date:  2008       Impact factor: 5.986

6.  Frontal white matter anisotropy and antidepressant remission in late-life depression.

Authors:  Warren D Taylor; Maragatha Kuchibhatla; Martha E Payne; James R Macfall; Yvette I Sheline; K Ranga Krishnan; P Murali Doraiswamy
Journal:  PLoS One       Date:  2008-09-24       Impact factor: 3.240

Review 7.  Brain Structural Effects of Antidepressant Treatment in Major Depression.

Authors:  Nicola Dusi; Stefano Barlati; Antonio Vita; Paolo Brambilla
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.